These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7105621)

  • 1. Hydralazine and furosemide kinetics.
    Nomura A; Yasuda H; Katoh K; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1982 Sep; 32(3):303-6. PubMed ID: 7105621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of furosemide in congestive heart failure.
    Nomura A; Yasuda H; Minami M; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1981 Aug; 30(2):177-82. PubMed ID: 7249502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of dihydralazine with furosemide in hypertonic patients.
    Siegmund W; Kairies M; Franke G; Donner I; Biebler KE
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):148-51. PubMed ID: 3557742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.
    Chaturvedi PR; O'Donnell JP; Nicholas JM; Shoenthal DR; Waters DH; Gwilt PR
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):123-8. PubMed ID: 3557737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.
    Andreasen F; Mikkelsen E
    Eur J Clin Pharmacol; 1977 Aug; 12(1):15-22. PubMed ID: 902673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide absorption altered in decompensated congestive heart failure.
    Vasko MR; Cartwright DB; Knochel JP; Nixon JV; Brater DC
    Ann Intern Med; 1985 Mar; 102(3):314-8. PubMed ID: 3970471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of systemic availability of oral hydralazine in heart failure.
    Crawford MH; Ludden TM; Kennedy GT
    Clin Pharmacol Ther; 1985 Nov; 38(5):538-43. PubMed ID: 4053489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral hydralazine in chronic heart failure.
    Hanson A; Johansson BW; Wernersson B; Wåhlander LA
    Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and urinary kinetics of furosemide in newborn infants.
    Tuck S; Morselli P; Broquaire M; Vert P
    J Pediatr; 1983 Sep; 103(3):481-5. PubMed ID: 6886918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of furosemide in patients with congestive heart failure.
    Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K
    Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furosemide kinetics and dynamics after kidney transplant.
    Smith DE; Gambertoglio JG; Vincenti F; Benet LZ
    Clin Pharmacol Ther; 1981 Jul; 30(1):105-13. PubMed ID: 7016396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of probenecid on furosemide kinetics and natriuresis in man.
    Honari J; Blair AD; Cutler RE
    Clin Pharmacol Ther; 1977 Oct; 22(4):395-401. PubMed ID: 902452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of furosemide and trimethazidine on kinetic behavior and hypotensive effect of hydralazine in rats.
    Ogiso T; Iwaki M; Ohtori A
    J Pharmacobiodyn; 1986 Jan; 9(1):1-11. PubMed ID: 3712206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracardial effects of oral ibopamine versus furosemide in patients with mild or moderate heart failure. A double-blind, randomized trial.
    Wehling M; Zimmermann J; Theisen K
    Cardiology; 1990; 77 Suppl 5():81-8. PubMed ID: 2279257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function.
    Talseth T
    Eur J Clin Pharmacol; 1976 Sep; 10(5):311-7. PubMed ID: 976304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nadolol in hypertensive patients maintained on long-term hemodialysis.
    Michaels RS; Duchin KL; Akbar S; Meister J; Levin NW
    Am Heart J; 1984 Oct; 108(4 Pt 2):1091-4. PubMed ID: 6148869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydralazine kinetics in hypertensive patients after intravenous administration.
    Ludden TM; Shepherd AM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):736-42. PubMed ID: 7438689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.